» Articles » PMID: 36367172

Lycorine Upregulates the Expression of RMB10, Promotes Apoptosis and Inhibits the Proliferation and Migration of Cervical Cancer Cells

Overview
Journal Int J Mol Med
Specialty Genetics
Date 2022 Nov 11
PMID 36367172
Authors
Affiliations
Soon will be listed here.
Abstract

Although there are numerous treatment strategies, including surgery and chemotherapy, the prognosis of cervical cancer remains far from satisfactory. There is an urgent need to develop more effective, more tolerable and safer therapeutics for the treatment of cervical cancer. Lycorine is a natural plantextract that has been previously found to confer anti‑tumor activities. Therefore, in the present study, the effects of lycorine and its possible mechanism of action in cervical cancer were investigated. Cell Counting Kit‑8, wound healing and Transwell assays were used to verify the proliferation and migration of HeLa cells following lycorine intervention. The results demonstrated that lycorine significantly inhibited the proliferation and migration of HeLa cells. RNA binding motif 10 (RBM10) is a protein associated with apoptosis. It has been suggested that lycorine can affect the expression of RBM10. Flow cytometry demonstrated that lycorine may inhibit the initiation and progression of cervical cancer by promoting apoptosis, which may be mediated through the upregulation of RBM10 expression and increasing TNF‑α levels. Xenograft mouse experiments indicated that when lycorine was injected through the tail vein, HeLa tumor growth was inhibited. Mechanistically, western blotting demonstrated that lycorine significantly inhibited the activation of the Akt signaling pathway and potentially reversed epithelial‑mesenchymal transition, which was also mediated by RBM10. Furthermore, following RBM10 knockdown with small interfering‑RNA, the inhibitory effects of lycorine on cervical cancer was significantly abrogated. Overall, results of the present study suggest that lycorine can upregulate the expression of RBM10 and inhibit the proliferation and migration of cervical cancer cells.

Citing Articles

Ferroptosis in Renal Cancer Therapy: A Narrative Review of Drug Candidates.

Yu L, Qiu Y, Tong X Cancers (Basel). 2024; 16(18).

PMID: 39335103 PMC: 11430741. DOI: 10.3390/cancers16183131.


Benzoindolizidine Alkaloids Tylophorine and Lycorine and Their Analogues with Antiviral, Anti-Inflammatory, and Anticancer Properties: Promises and Challenges.

Di Sotto A, Valipour M, Azari A, Di Giacomo S, Irannejad H Biomedicines. 2023; 11(10).

PMID: 37892993 PMC: 10603990. DOI: 10.3390/biomedicines11102619.


Arctigenin hinders the invasion and metastasis of cervical cancer cells via the FAK/paxillin pathway.

Liao D, Liu Y, Li C, He B, Zhou G, Cui Y Heliyon. 2023; 9(6):e16683.

PMID: 37292259 PMC: 10245248. DOI: 10.1016/j.heliyon.2023.e16683.

References
1.
Davies-Oliveira J, Smith M, Grover S, Canfell K, Crosbie E . Eliminating Cervical Cancer: Progress and Challenges for High-income Countries. Clin Oncol (R Coll Radiol). 2021; 33(9):550-559. DOI: 10.1016/j.clon.2021.06.013. View

2.
Buskwofie A, David-West G, Clare C . A Review of Cervical Cancer: Incidence and Disparities. J Natl Med Assoc. 2020; 112(2):229-232. DOI: 10.1016/j.jnma.2020.03.002. View

3.
Ji Y, Xie S, Jiang L, Liu L, Li L, Luo L . Increased cell apoptosis in human lung adenocarcinoma and tumor growth inhibition by , a tumor suppressor gene. Oncol Lett. 2017; 14(4):4663-4669. PMC: 5649569. DOI: 10.3892/ol.2017.6765. View

4.
Castillo Ferrer C, Berthenet K, Ichim G . Apoptosis - Fueling the oncogenic fire. FEBS J. 2020; 288(15):4445-4463. PMC: 8451771. DOI: 10.1111/febs.15624. View

5.
Zheng M, Zhou Q, Liu X, Wang C, Liu G . CTHRC1 overexpression promotes cervical carcinoma progression by activating the Wnt/PCP signaling pathway. Oncol Rep. 2019; 41(3):1531-1538. PMC: 6365690. DOI: 10.3892/or.2019.6963. View